Literature DB >> 26120376

Magnetic resonance guided high-intensity focused ultrasound ablation of musculoskeletal tumors.

Raffi S Avedian1, Garry Gold2, Pejman Ghanouni2, Kim Butts Pauly2.   

Abstract

This article reviews the fundamental principles and clinical experimental uses of magnetic resonance guided high-intensity focused ultrasound (MRgHIFU) ablation of musculoskeletal tumors. MRgHIFU is a noninvasive treatment modality that takes advantage of the ability of magnetic resonance to measure tissue temperature and uses this technology to guide high-intensity focused ultrasound waves to a specific focus within the human body that results in heat generation and complete thermal necrosis of the targeted tissue. Adjacent normal tissues are spared because of the accurate delivery of thermal energy, as well as, local blood perfusion that provides a cooling effect. MRgHIFU is approved by the Food and Drug Administration for the treatment of uterine fibroids and is used on an experimental basis to treat breast, prostate, liver, bone, and brain tumors.

Entities:  

Keywords:  bone tumors; focused ultrasound; magnetic resonance thermometry; noninvasive; palliation; sarcoma

Year:  2011        PMID: 26120376      PMCID: PMC4479407          DOI: 10.1097/BCO.0b013e318220dad5

Source DB:  PubMed          Journal:  Curr Orthop Pract        ISSN: 1940-7041


  40 in total

1.  Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence.

Authors:  S S Bielack; B Kempf-Bielack; K Winkler
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis.

Authors:  L Raffaelli; L Scaramuzzo; P Rossi Iommetti; C Graci; G Maccauro; P F Manicone
Journal:  J Biol Regul Homeost Agents       Date:  2010 Apr-Jun       Impact factor: 1.711

4.  The feasibility of using MRI to monitor and guide noninvasive ultrasound surgery.

Authors:  K Hynynen; C Damianou; A Darkazanli; E Unger; J F Schenck
Journal:  Ultrasound Med Biol       Date:  1993       Impact factor: 2.998

5.  The acoustic properties of normal and imbedded bovine bone as measured by acoustic microscopy.

Authors:  M C Zimmerman; A Prabhakar; B V Chokshi; N Budhwani; H Berndt
Journal:  J Biomed Mater Res       Date:  1994-08

6.  Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma.

Authors:  M Sluga; R Windhager; S Lang; H Heinzl; S Bielack; R Kotz
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

7.  Osteosarcoma: chemotherapy-induced changes at MR imaging.

Authors:  H C Holscher; J L Bloem; D Vanel; J Hermans; M A Nooy; A H Taminiau; M Henry-Amar
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

Review 8.  Osteolytic bone metastasis in breast cancer.

Authors:  T Yoneda; A Sasaki; G R Mundy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 9.  Palliative radiotherapy trials for bone metastases: a systematic review.

Authors:  Edward Chow; Kristin Harris; Grace Fan; May Tsao; Wai M Sze
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

10.  A NEW METHOD FOR THE GENERATION AND USE OF FOCUSED ULTRASOUND IN EXPERIMENTAL BIOLOGY.

Authors:  J G Lynn; R L Zwemer; A J Chick; A E Miller
Journal:  J Gen Physiol       Date:  1942-11-20       Impact factor: 4.086

View more
  1 in total

1.  Oxytocin Administration in High-Intensity Focused Ultrasound Treatment of Myomata.

Authors:  Tomasz Lozinski; Justyna Filipowska; Piotr Krol; Anna Kubaty; Piotr Wegrzyn
Journal:  Biomed Res Int       Date:  2018-07-02       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.